esions in the GI system with a high degree of accuracy. The company’s line of RX Biliary System devices designed to provide greater access and control for physicians to diagnose and treat challenging conditions of the bile ducts, such as removing gallstones, opening obstructed bile ducts and obtaining biopsies in suspected tumors. Interventional Bronchoscopy The company markets devices to diagnose, treat and ease pulmonary disease systems within the airway and lungs. Its products are designed to help perform biopsies, retrieve foreign bodies from the airway, open narrowings of an airway, stop internal bleeding, and ease symptoms of some types of airway cancers. The company’s product line includes pulmonary biopsy forceps; transbronchial aspiration needles; cytology brushes; tracheobronchial stents used to dilate narrowed airway passages or for tumor management; and the Alair Bronchial Thermoplasty System for the treatment of severe persistent asthma. Urology and Pelvic Health The company’s Urology and Pelvic Health business develops, manufactures and sells devices to treat various urological and pelvic conditions. Within its Urology business, the company sells various products designed to treat patients with urinary stone disease and benign prostatic hyperplasia (BPH). The company offers a line of stone management products, including ureteral stents, wires, lithotripsy devices, stone retrieval devices, sheaths, balloons and catheters. Within its Pelvic Health business, the company markets a range of devices for the treatment of conditions, such as stress urinary incontinence, pelvic floor reconstruction (rebuilding of the anatomy to its original state), menorrhagia (excessive menstrual bleeding), uterine fibroids and polyps, and erectile dysfunction. The company offers mid-urethral sling products, sling materials, graft materials, pelvic floor reconstruction kits, and suturing devices. It markets its Genesys Hydro ThermAblator system, an ablation system designed to ablate the endometrial lining of the uterus in premenopausal women with menorrhagia. In the U.S., the company launched the Symphion System for the removal of intrauterine fibroids and polyps. In August 2015, the company completed the AMS Portfolio Acquisition, which includes men's health and prostate health businesses, from Endo International plc. The AMS Portfolio Acquisition includes the procurement of products for the treatment of various urologic conditions, including the minimally invasive GreenLight XPS and HPS Laser Therapy Systems for treating BPH, the AMS 700 Inflatable Penile Prosthesis for treating erectile dysfunction, and the AMS 800 Urinary Control System for treating male stress urinary incontinence. Neuromodulation The company’s Neuromodulation business offers the Precision and Precision Spectra Spinal Cord Stimulator (SCS) Systems, used for the management of chronic pain. The Precision Spectra System is SCS system with 32 contacts and 32 dedicated power sources and is designed to provide improved pain relief to a range of patients who suffer from chronic pain. Additionally, in June 2015, the company launched the Precision Novi SCS System in Europe. The Precision Novi System offers patients and physicians the 16-contact high capacity primary cell (PC), also referred to as non-rechargeable, device for the treatment of chronic pain. The company also has CE-mark approval for use of its Vercise Deep Brain Stimulation (DBS) System in Europe for the treatment of Parkinson's disease, tremor and intractable primary and secondary dystonia, a neurological movement disorder characterized by involuntary muscle contractions. In September 2015, the company gained CE-mark approvals for the Vercise PC DBS System with its Navigator programming software. The system allows for programming flexibility to treat a greater range of patients throughout their disease progression. In addition, the company received CE Mark approval for the only commercially available Directional Lead powered by current steering. The Directional Lead uses multi-directional stimulation for greater precision, intended to minimize side effects for patients. The comp
boston scientific corp
(BSX:New York Consolidated)
300 Boston Scientific Way
Marlborough, MA 01752
|Astellas Pharma Inc||¥1,446 JPY||-51.50|
|Baxter International Inc||$44.39 USD||-0.32|
|Olympus Corp||¥4,205 JPY||-140.00|
|St Jude Medical Inc||$75.85 USD||-0.45|
|Zimmer Biomet Holdings Inc||$114.90 USD||-1.03|
|View Industry Companies|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact BOSTON SCIENTIFIC CORP, please visit www.bostonscientific.com. Company data is provided by Capital IQ. Please use this form to report any data issues.